Marker Therapeutics, Inc.

Developing non-genetically modified T cell immunotherapies for hematologic and solid tumors.

MRKR | US

Overview

Corporate Details

ISIN(s):: US57055L1070 (+1 more)
LEI:
Country:: United States of America
Address:: 2450 HOLCOMBE BLVD, 77021 HOUSTON
Website:: https://markertherapeutics.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company developing next-generation, non-genetically modified T cell-based immunotherapies for hematologic malignancies and solid tumors. The company's core technology, Multi-Antigen Recognizing (MAR) T cells, expands a patient's natural T cells to recognize and eliminate tumors expressing multiple antigens. This approach aims to provide durable anti-tumor responses with a favorable safety profile compared to genetically engineered cell therapies. The technology was developed at Baylor College of Medicine. Its lead product candidate, MT-601, is being evaluated in a Phase 1 study for lymphoma patients who have relapsed or are ineligible for anti-CD19 CAR-T cell therapy.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Marker Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Marker Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Marker Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
MEDIPOSTCO.,LTD. Develops cord blood stem cell therapies for osteoarthritis & infant lung disease, plus banking.	South Korea	078160
MediWound Ltd. Develops enzymatic therapies for non-surgical tissue repair in burns and chronic wounds.	United States of America	MDWD
Medizen Humancare Inc Co., Ltd Offers DTC genetic testing and genomic analysis for personalized disease risk prediction.	South Korea	236340
Medy-Tox Inc. Develops and markets botulinum toxins and dermal fillers for global aesthetic & therapeutic use.	South Korea	086900
MeiraGTx Holdings plc Develops genetic medicines for eye, salivary gland, and CNS disorders using gene regulation tech.	United States of America	MGTX
Meito Sangyo Co., Ltd. Produces food products and specialty chemicals for industrial and pharmaceutical applications.	Japan	2207
Merck & Co., Inc. A global biopharma developing innovative medicines, vaccines, and animal health products.	United States of America	MRK
Mereo BioPharma Group plc A clinical-stage biopharma developing and commercializing novel therapies for rare diseases.	United States of America	MREO
Mersana Therapeutics, Inc. Developing innovative antibody-drug conjugates using proprietary platforms to treat cancer.	United States of America	MRSN
Merus N.V. Develops multispecific antibody therapies that harness the immune system to fight cancer.	United States of America	MRUS